Xencor [XNCR] vs Amylyx [AMLX] Detailed Stock Comparison

Xencor Inc.

NASDAQ
Loading...

Amylyx Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Xencor Inc. wins in 6 metrics, Amylyx Pharmaceuticals Inc. wins in 9 metrics, with 0 ties. Amylyx Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Xencor Inc. Amylyx Pharmaceuticals Inc. Better
P/E Ratio (TTM) -10.48 2.54 Amylyx Pharmaceuticals Inc.
Price-to-Book Ratio 1.47 6.31 Xencor Inc.
Debt-to-Equity Ratio 29.54 1.95 Amylyx Pharmaceuticals Inc.
PEG Ratio 0.12 -0.06 Xencor Inc.
EV/EBITDA -3.55 -10.64 Xencor Inc.
Profit Margin (TTM) -73.20% 0.00% Amylyx Pharmaceuticals Inc.
Operating Margin (TTM) -189.92% 0.00% Amylyx Pharmaceuticals Inc.
Return on Equity -14.07% -61.59% Xencor Inc.
Return on Assets (TTM) -12.14% -36.41% Xencor Inc.
Free Cash Flow (TTM) $-138.27M $-123.48M Amylyx Pharmaceuticals Inc.
1-Year Return 48.50% 178.64% Amylyx Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 7.58 N/A N/A
Enterprise Value $591.95M $1.63B Amylyx Pharmaceuticals Inc.
EV/Revenue Ratio 4.71 N/A N/A
Revenue per Share (TTM) $2 N/A N/A
Earnings per Share (Diluted) $-1.24 $-1.53 Xencor Inc.
Beta (Stock Volatility) 0.99 -0.21 Amylyx Pharmaceuticals Inc.
Short % of Float 19.84% 13.92% Amylyx Pharmaceuticals Inc.

Xencor Inc. vs Amylyx Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

XNCR
AMLX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Xencor Inc.1.87%-2.56%-14.52%-4.99%-34.03%-23.46%
Amylyx Pharmaceuticals Inc.-0.68%-6.18%-19.81%-6.45%-7.11%15.59%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Xencor Inc.48.50%-57.10%-67.41%-17.61%53.09%53.09%
Amylyx Pharmaceuticals Inc.178.64%-43.01%-20.59%-20.59%-20.59%-20.59%

Performance & Financial Health Analysis: Xencor Inc. vs Amylyx Pharmaceuticals Inc.

MetricXNCRAMLX
Market Information
Market Cap i$951.94M$1.91B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i670,2301,099,346
90 Day Avg. Volume i848,4071,107,595
Last Close$11.42$13.20
52 Week Range$6.92 - $18.69$4.76 - $18.60
% from 52W High-38.90%-29.05%
All-Time High$58.35 (Feb 22, 2021)$41.93 (Jan 30, 2023)
% from All-Time High-80.43%-68.52%
Growth Metrics
Quarterly Revenue Growth-0.47%N/A
Quarterly Earnings Growth-0.60%N/A
Financial Health
Profit Margin (TTM) i-0.73%0.00%
Operating Margin (TTM) i-1.90%0.00%
Return on Equity (TTM) i-0.14%-0.62%
Debt to Equity (MRQ) i29.541.95
Cash & Liquidity
Book Value per Share (MRQ)$8.84$2.78
Cash per Share (MRQ)$7.47$2.87
Operating Cash Flow (TTM) i$-135,116,992$-123,343,000
Levered Free Cash Flow (TTM) i$-39,165,124$-66,994,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Xencor Inc. vs Amylyx Pharmaceuticals Inc.

MetricXNCR (Apr 26, 2026)AMLX (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-10.482.54
Forward P/E i-4.27-14.30
PEG Ratio i0.12-0.06
Price to Sales (TTM) i7.58N/A
Price to Book (MRQ) i1.476.31
Market Capitalization
Market Capitalization i$951.94M$1.91B
Enterprise Value i$591.95M$1.63B
Enterprise Value Metrics
Enterprise to Revenue i4.71N/A
Enterprise to EBITDA i-3.55-10.64
Risk & Other Metrics
Beta i0.99-0.21
Book Value per Share (MRQ) i$8.84$2.78

Financial Statements Comparison: Xencor Inc. vs Amylyx Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricXNCR (2025)AMLX (2025)
Revenue/Sales i125.58M0
Cost of Goods Sold iN/A0
COGS % of Revenue i0.0%-
Gross Profit iN/A0
Gross Margin i0.0%-
Research & Development i239.43M90.40M
Operating Income (EBIT) i-177.50M-153.29M
Operating Margin i-141.4%-
EBITDA i-139.54M-152.77M
EBITDA Margin i-111.1%-
Pre-Tax Income i-89.63M-144.69M
Pre-Tax Income % of Revenue i-71.4%-
Income Tax i2.50M46,000
Income Tax % of Revenue i2.0%-
Net Income (Profit) i-92.14M-144.74M
Profit Margin i-73.4%-

Balance Sheet & Liquidity Metrics

MetricXNCR (2025)AMLX (2025)
Cash & Equivalents i54.07M226.65M
Total Current Assets i599.82M323.67M
Total Current Assets % of Revenue i477.7%-
Total Current Liabilities i95.91M22.69M
Total Current Liabilities % of Revenue i76.4%-
Long-Term Debt i141.22M4.70M
Long-Term Debt % of Revenue i112.5%-
Total Shareholders Equity i635.59M305.26M
Retained Earnings i-795.96M-751.43M
Retained Earnings % of Revenue i-633.8%-
Property, Plant & Equipment i81.34M5.18M

Cash Flow Statement Comparison

MetricXNCR (2025)AMLX (2025)
Operating Cash Flow i-62.53M-115.20M
Operating Cash Flow % of Revenue i-49.8%-
Capital Expenditures i-3.15M-138,000
Free Cash Flow i-138.27M-123.48M
FCF Margin i-110.1%-
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricXNCRAMLX
Shares Short i10.31M14.23M
Short Ratio i10.9813.56
Short % of Float i19.84%13.92%
Shares Outstanding i71.87M109.88M
Float Shares i53.85M82.88M
% Held by Insiders i1.26%7.95%
% Held by Institutions i119.35%104.29%
% Held by Public i-20.61%-12.24%

Dividend Analysis & Yield Comparison: Xencor Inc. vs Amylyx Pharmaceuticals Inc.

MetricXNCRAMLX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A